ORIC Pharmaceuticals is a US-based clinical-stage biopharmaceutical company that specializes in developing cancer treatments. Its product candidates are aimed at combating resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also working on developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms.